儿童重症允许性血压目标:PRESSURE随机临床试验
该多中心、非盲、实用性随机临床试验在3国23个PICU纳入1900例接受有创通气和血管活性药物治疗低血压的危重患儿,比较允许性平均动脉压目标(高于年龄第5百分位)与常规治疗。结果显示两组30天死亡和侵入性通气时长复合终点无显著差异,允许性目标组去甲肾上腺素等效总剂量中位数降低37.5%,存活者PICU住院时间更短。
要点
- 允许性MAP目标未显著改善30天死亡与有创通气时长复合终点。
- 允许性目标使去甲肾上腺素等效总剂量中位数降低37.5%。
- 存活者PICU住院时间在允许性目标组更短。
核心结论
- 在低血压危重患儿中,采用允许性MAP目标与常规治疗相比,30天死亡和侵入性通气时长复合终点无显著差异。
研究设计与样本
- 多中心、非盲、实用性随机临床试验,在3国23个PICU开展。
- 允许性MAP目标组957例,常规治疗组943例;主要结局分析纳入允许性组910例、常规组904例。
- 参与者中位(IQR)年龄4(0-10)岁,44.8%为女性。
主要发现
- 使用血管活性药物期间中位(IQR)MAP在允许性组为58(51-63)mm Hg,常规组为61(54-67)mm Hg。
- 允许性MAP目标使去甲肾上腺素等效总剂量中位数较常规组降低37.5%。
- 7项次要结局中6项相似,存活者中位(IQR)PICU住院时间允许性组为159(79-286)小时,常规组为166(92-319)小时(概率指数0.53,95%CI 0.50-0.56)。
- 肾脏替代治疗接受率和不良事件两组无差异。
临床怎么用
- 对接受有创通气和血管活性药物的低血压危重患儿,可考虑允许性MAP目标以减少血管活性药物暴露。
- 允许性MAP目标未改善30天死亡与通气复合结局,需结合个体情况权衡。
局限性
- 研究为非盲设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vasoactive drugs are often given to critically ill children to treat hypotension. However, optimal mean arterial pressure (MAP) targets are unknown. OBJECTIVE: To evaluate whether adopting a permissive MAP target, and thereby potentially reducing exposure to vasoactive drugs, improves outcomes in hypotensive critically ill children. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, unblinded, pragmatic randomized clinical trial was conducted in 23 pediatric intensive care units (PICUs) in 3 countries. Critically ill children receiving invasive ventilation and vasoactive drugs for hypotension were enrolled between November 2021 and May 2026. Follow-up to the 30-day outcome was completed in June 2026. INTERVENTIONS: Patients randomized to the intervention (n = 957) were assigned a permissive MAP target greater than the fifth percentile for age. Patients in the control group (n = 943) received usual care with MAP target set by the attending physician. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of mortality and duration of invasive ventilation at 30 days. Secondary outcomes included mortality at PICU discharge, time to cessation of invasive ventilation, receipt and duration of kidney replacement therapy in PICU at 30 days, and length of PICU and hospital stay. RESULTS: Of 1900 randomized patients, 910 in the permissive MAP target group and 904 in the usual care group were included for analysis of the primary outcome. Participants had a median (IQR) age of 4 (0-10) years and 44.8% were female; baseline characteristics were similar between the groups. Median (IQR) MAP while receiving vasoactive drugs was 58 (51-63) mm Hg in the permissive MAP target group and 61 (54-67) mm Hg in the usual care group. A permissive MAP target led to a 37.5% reduction in median norepinephrine-equivalent total dose compared with the usual care group. There was no significant difference between the groups in the primary outcome (probabilistic index, 0.52 [95% CI, 0.49-0.54]; P = .23). Six of the 7 secondary outcomes were similar between the groups, except median (IQR) PICU length of stay was significantly shorter in survivors in the permissive MAP target vs usual care group (159 [79-286] vs 166 [92-319] hours); probabilistic index, 0.53 [95% CI, 0.50-0.56]). Receipt of kidney replacement therapy and adverse events did not differ between the groups. CONCLUSIONS AND RELEVANCE: Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
引用
- Inwald DP, Laing E, Broomhall JM, et al. Permissive Blood Pressure Targets in Pediatric Critical Care: The PRESSURE Randomized Clinical Trial. JAMA. 2026. PMID: 42806496. doi:10.1001/jama.2026.19747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。